Piotr Potemski

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 196 citations · Full text

Overall Survival, Gastrointestinal Oncology, Medicine +7

Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer

Piotr Potemski, Renata Kusińska, Cezary Watała et al. · Oncology · 2005 · 104 citations

CD151 Regulates Tumorigenesis by Modulating the Communication between Tumor Cells and Endothelium

Rafał Sądej, Hanna Romańska, Gouri Baldwin et al. · Molecular Cancer Research · 2009 · 88 citations · Full text

WWOX—the FRA16D cancer gene: Expression correlation with breast cancer progression and prognosis

Elżbieta Płuciennik, Renata Kusińska, Piotr Potemski et al. · European Journal of Surgical Oncology · 2005 · 82 citations

Tumor Biology, Breast Oncology, Oncology +10